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Abstract  Drug  reaction  with  eosinophilia  and  systemic  symptoms  (DRESS)  syndrome  is a
severe, idiosyncratic  reaction  characterized  by  diffuse  maculopapular  rash,  facial  edema,  lym-
phadenopathy,  fever,  eosinophilia  and/or  other  leukocyte  abnormalities,  and  involvement  of
internal organs  as  liver,  kidney,  heart  and  lung.
Diagnosing  this  entity  is specifically  complicated  due  to  the  multiplicity  of  organs  involved.
DRESS syndrome  must  be recognized  promptly  and  the  causative  drug  withdrawn  in  order  to
improve patient  outcomes.  Indeed,  it  is a  potentially  life-threatening  condition,  with  a  reported
mortality between  5  and  20%.
We  describe  a  case  of  a  22-year  old  woman  admitted  to  our  hospital  with  acute  diffuse,
pruritic rash associated  with  crampy  abdominal  pain,  vomiting,  diarrhea  and fever  three  weeks
after starting  sulfasalazine  therapy.
Initially,  laboratory  parameters  revealed  normal  white  blood  cell  count  and normal  liver
enzymes,  but  during  hospitalization,  eosinophilia  developed  and  liver  enzymes,  including
transaminases  and  cholestatic  parameters,  dramatically  increased.  The  diagnostic  of  DRESS  syn-
drome was  made  and  sulfasalazine  was  withdrawn  and  as  there  were  signs  of  disease  severity,
systemic  corticotherapy  was  initiated,  with  gradually  improvement  of  the  rash  and  symptoms
resolution.
The patient  was  discharged  home  after  thirty  days  of  hospitalization.
©  2016  Sociedade  Portuguesa  de Gastrenterologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is
an open  access  article  under  the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Resumo  A síndrome  DRESS  (Drug  Reaction  with  Eosinophilia  and  Systemic  Symptoms)  é  uma
reac¸ão de  hipersensibilidade  sistémica  caracterizada  por dermatite  exfoliativa  e rash  maculo-
papular,  linfadenopatia,  febre,  eosinofilia  e envolvimento  de órgãos  internos,  como  o  fígado  e o
trato gastrointestinal.  O  diagnóstico  é  difícil  porque  as suas  manifestac¸ões  clínicas  mimetizam
as encontradas  noutras  doenc¸as sistémicas  graves.
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adverso
Esta  síndrome  deve  ser  reconhecida  precocemente  e o  fármaco  responsável  suspenso  com  o
intuito de  melhorar  o  prognóstico  do  doente.  É,  de facto,  uma  condic¸ão  potencialmente  fatal,
com uma  mortalidade  entre  5  e  20%.
Apresentamos  o caso  clínico  de uma  doente  de  22  anos,  que  recorreu  ao  servic¸o de urgência
por um  quadro  clínico  caracterizado  por  rash  pruriginoso  associado  a  dor  abdominal  tipo  cólica,
vómitos, diarreia  e  febre  3  semanas  após  início  de terapêutica  com  sulfassalazina.
Inicialmente,  a  avaliac¸ão  laboratorial  não  revelou  alterac¸ões,  mas  durante  o internamento,
desenvolveu-se  eosinofilia  e  as  provas  hepáticas,  incluindo  transaminases  e parâmetros  de
colestase,  aumentaram  de forma  significativa.
Foi efetuado  o diagnóstico  de síndrome  de  DRESS,  a  sulfassalazina  foi suspensa  e  iniciou
corticoterapia  sistémica,  dados  os sinais  de gravidade  da  doenc¸a.
Verificou-se  melhoria  gradual  da  sintomatologia,  tendo  tido  alta  clínica  após  trinta  dias  de
internamento.
© 2016  Sociedade  Portuguesa  de Gastrenterologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este
e´ um artigo  Open  Access  sob  uma licenc¸a  CC BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
1. Introduction
Drug  reaction  with  eosinophilia  and  systemic  symptoms
(DRESS)  syndrome  is  a  distinct,  severe,  idiosyncratic  reac-
tion  to  a  drug  characterized  by  a  prolonged  latency  period.1
The  estimated  incidence  of  this syndrome  ranges  from  1
in  1000  to  1  in  10,000  drug  exposures.2
The  main  culprit  drugs  are carbamazepine  and  allopuri-
nol,  even  though  almost  50  drugs  have  been  described  to
have  caused  this  syndrome.2
The  hallmark  features  of  DRESS  syndrome,  not always
detectable  at  the  same  time,  include  diffuse  maculopapular
rash,  facial  edema,  lymphadenopathy,  fever,  hematologic
abnormalities  (eosinophilia  or  atypical lymphocytes),3 and
involvement  of internal  organs.4
It  is  difficult  to  diagnose,  as  many  of  its  clinical  features
mimic  those  found  with  other  serious  systemic  disorders.5
However,  early  recognition  of the syndrome  with  the cessa-
tion  of  the  causative  drug is  essential  in improving  patient
outcome.6
2. Clinical case
A 22-year  old  woman,  born  in  Cape  Verde,  was  being  fol-
lowed  in  the  rheumatology  outpatient  setting  for  migratory
oligoarthritis  for  seven  years.
For  this  reason,  sulfasalazine  was  started.  After  three
weeks  of treatment,  she  was  admitted  to  our  emergency
department  with  an acute  diffuse,  pruritic  rash. On admis-
sion,  sulfasalazine  was  withdrawn  and  hydrocortisone  was
administered.  Because  she  had  no  signs of  end-organ  dam-
age  or  laboratory  abnormalities,  she  was  discharged  home.
After  3  days,  she  returned  to  our  emergency  department
with  the  same  clinical  picture,  now  with  crampy  abdominal
pain, vomiting,  diarrhea  and  fever.
On admission,  mental  status  was  normal,  body  temper-
ature  was  36.3 ◦C,  blood  pressure  was  140/84  mmHg,  the
heart  rate  was  76  beats  per  minute.  She  was  alert  and  ori-
ented  and in  no  apparent  distress.
Her  skin  had  disseminated  dermatosis  with  papules;  there
were  also  some  pustules  on  the dorsal  area, upper  and  lower
limbs.  There  was  no  evidence  of lymphadenopaty  or  hep-
atosplenomegaly.
Laboratory  tests  showed  normal white  blood  cell
count  (6900  cell/L)  with  absolute  eosinophil  count of
2300  cell/L, with  no atypical  lymphocytes,  liver  parame-
ters  values:  aspartate  transaminase  (AST)  58  IU/L; alanine
transaminase  (ALT)  68  IU/L;  alkaline  phosphatase  (AP)
73  IU/L; gamma-glutamyl  transferase  (gGT)  50 IU/L;  lactate
dehydrogenase  (LDH)  240  U/L;  total  bilirubin  0.25  mg/dL,
with  a  normal  prothrombin  time  (PT);  serum  creatinine  level
of  1.01  mg/dL;  serum  urea  level  of  35  mg/dL;  C-reactive
protein  6.64  mg/dL.
Dermatology  was  consulted  and  considered  the skin
lesions  could  be due  to  acute  generalized  exanthematous
pustulosis  induced  by  sulfasalazine  (that  had  already  been
withdrawn)  and  a biopsy  of  one  of  the  skin  lesions  was  per-
formed.  Based  on  this  diagnosis,  prednisolone  20  mg/day
and  hydroxyzine  25  mg  tid  were  initiated,  with  gradually
improvement  of  the rash.
On  the  fourth  day  of hospitalization,  she  developed
eosinophilia  (5.6  ×  103/L), liver  enzymes  raised  (AST
122  IU/L;  ALT  207  IU/L;  AP  184  IU/L;  gGT  217  IU/L;  LDH
718  U/L), maintaining  fever  and  skin  rash.
Due  to sore  throat  on  the sixth  day after  admission,  Oto-
laryngology  was  consulted  and observed  tonsillitis  with  a
grayish-white  coating,  recommending  therapy  with  amoxi-
cillin  and  clavulanic  acid.
Liver  enzymes  continued  increasing  reaching  maximum
values  on the  eleventh  day of  hospitalization  (AST  3591  IU/L;
ALT  2102  IU/L;  AP 573  IU/L; gGT  1591  IU/L;  LDH 1940  U/L
total  bilirubin  2.11  mg/dL,  also  with  elevation  of  PT  (27,
with  normal  value  between  10  and 14). Abdominal  ultra-
sound  revealed  only  portal  accentuation  pattern.  Due
to  the suspicion  of  toxic  hepatitis,  antibiotherapy  was
withdrawn.
Serologic  tests  for  acute  infection  by  hepatotropic  virus
--  hepatitis  A,  B,  C,  E,  Epstein--Barr  virus,  Citomegalovirus,
human  herpesvirus  (HHV)-6  (evaluated  by  enzyme-linked
immunosorbent  assay)  were  negative.
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Skin  biopsy  showed  superficial  perivascular  lymphocytic
infiltration.
The diagnosis  of  DRESS  syndrome  was  made  [using  RegiS-
CAR  criteria,7 the patient  had  4  characteristics  --  acute  skin
rash,  fever  (>38 ◦C), involvement  of  liver,  and  eosinophils
above  the  laboratory  limits)].  For  this reason,  prednisolone
was  increased  to  60 mg/day  (1  mg/kg/day)  with  a progres-
sive  improvement  in the rash.  Similarly,  liver  enzymes  which
started  reducing  gradually,  since  one day after  antibiother-
apy  withdrawal,  returned  to  normal.
The  patient  was  discharged  home  after  thirty  days  of
hospitalization  (on  60 mg  prednisolone/day),  with  the indi-
cation  to  gradually  reduce  corticosteroid  therapy  (slower
reduction).  After three  months  of  follow-up,  now  on  40  mg
prednisolone/day,  the  rash is  in remission.
3.  Discussion
Drug  Reaction  with  Eosinophilia  and  Systemic  Symptoms
(DRESS)  syndrome  formed  by  the  acronym  derived  from
the  term  ‘‘Drug  Rash  with  Eosinophilia  and  Systemic  Symp-
toms’’,6 was  introduced  by Bocquet  et  al.8 and  was  based
on  the  observation  of  Callot  et  al.9 who,  in  1996,  performed
a  retrospective  study  of 24  patients:  three  patients  had
had  subacute  papulonodular  or  infiltrated  plaques,  without
visceral  involvement,  while  the remaining  21  patients  had
an  acute  widespread  eruption,  with  fever,  enlarged  lymph
nodes,  and  multivisceral  involvement  developed  an acute
systemic  illness  with  eosinophilia.9
Although  a dermatosis  is  common  in  DRESS,  the
extent  of  skin  involvement  is variable  and therefore  the
‘R’  in  DRESS  was  subsequently  changed  from  ‘rash’  to
‘reaction’.6
The  pathogenesis  of  DRESS  syndrome  is  not  well
understood1 but  probably  involves  different  mechanisms,
including  detoxification  defects2 leading  to  reactive
metabolite  formation  and  subsequent  immunological  reac-
tions,  slow  acetylation,  and  reactivation1 of  human
herpes,10,11 including  Epstein--Barr  virus,  cytomegalovirus
and  HHV-6  and  -7.2,12
Many  drugs  have  been  reported  to  cause  DRESS  syn-
drome.  Cacoub  et  al.,  using  the RegiSCAR  scoring  system,
identified  44  drugs  implicated  in 172  cases  reported
between  January  1997  and  May  2009.2 In this  systematic
review,  the  most  common  culprit  drugs  were  aromatic  anti-
convulsants  (carbamazepine,  phenobarbital,  phenytoin),
allopurinol,  lamotrigine,  sulfasalazine,  nevirapine,  abacavir
and  mexiletine.2
This  syndrome  is  usually  characterized  by  long  latency
period  between  administration  of the  offending  drug  and
symptom  onset  with  a mean  of 3.9  weeks  (range  0.5--16
weeks).13 The  delayed  onset  in  relation  to  introduction
of  the  causative  drug  is  one  of the  important  features of
DRESS  that  can be  distinguished  from  other  types  of  drug
eruptions.14
DRESS  syndrome  is  a complex  syndrome  with  a  broad
spectrum  of clinical  features.1 The  reaction  often  starts  with
fever  shortly  followed  by  rash,  which  is  usually  pruritic,  and
variable  degrees  of  lymphadenopathy.14
The  cutaneous  eruption  consists  of a  morbilliform
rash.6 Initially,  the upper  trunk,  face,  upper  extremities
are  affected  and followed  by  involvement  of  lower
extremities.14
Swelling  of  the face,  with  marked  periorbital  involve-
ment  occurs  in about  25%  of  patients.6 Tender  lym-
phadenopathy  can be seen  in most  patients  (70--75%)6 early
in the  illness,  affecting  predominantly  cervical  nodes  or  gen-
eralized.  Bilateral  swelling  of  salivary  glands  with  severe
xerostomia  is  frequently  observed.14
Other  features  of  DRESS  include  visceral  involve-
ment  (hepatitis,  pneumonitis,  myocarditis,  pericarditis,6
nephritis,  pancreatitis,11 encephalitis,11,14 thyroiditis,14
colitis6).12,15 The  liver  is reported  to  be the  most frequently
involved  internal  organ.1,2,16
There  have  been  proposed  three  different  diagnos-
tic  criteria.1,11 According  to  Bocquet  et  al.  (in 1996),
the  diagnosis  is  established  if there  are at least  three
criteria  present:  skin  eruption,  hematologic  abnormalities
(eosinophilia  >1500/mm3;  presence  of atypical  lympho-
cytes),  and  systemic  involvement,  including  adenopathies
(>2  cm in diameter),  hepatitis  (transaminase  elevation  of at
least  twice  the normal  values),  interstitial  nephritis,  inter-
stitial  pneumonia,  or  carditis.8 The  Japanese  study  group
of  severe  cutaneous  adverse  reactions  to  drugs  (SCAR-J)
criteria  established  other  criteria  (in  2006):  maculopapular
rash  developing  >3  weeks  after  starting  with  the  suspected
drug,  prolonged  clinical  symptoms  two  weeks  after  dis-
continuing  the causative  drug,  fever  (>38 ◦C),  elevation
of  liver  enzyme  (ALT  >100  U/L),  leukocytosis  abnormal-
ities  [leukocytosis  (>11  × 103/L),  atypical  lymphocytosis
(>5%)  or  eosinophilia  (>1.5  × 103/L)],  lymphadenopathy,
and  HHV-6  reactivation.  Diagnosis  of  typical  DRESS  requires
the presence  of  all 7 criteria.17 The  European  registry  of
severe  cutaneous  adverse  reactions  to  drugs  and  collec-
tion  of biological  samples  (RegiSCAR)  group  suggested  the
following  criteria  (in  2007) for  hospitalized  patients:  reac-
tion  suspected  to be  drug  related,  acute  skin  rash,  fever
above  38 ◦C, enlarged  lymph  nodes  at at least  two  sites,
involvement  of  at least  one  internal  organ,  blood  count
abnormalities:  lymphocytes  above  or  below  the laboratory
limits,  eosinophils  above  the laboratory  limits  (in  percentage
or  absolute  count),  or  platelets  below  the  laboratory  limits.
At  least  3 of  these criteria  should  be present  for  DRESS.7
According  to  RegiSCAR  criteria,  the patient  described
here  met  4 characteristics:  acute  skin  rash, fever,  involve-
ment  of  liver  and  eosinophilia.
The diagnosis,  as  shown  in this  clinical  case,  can be
difficult  because  many  of  the clinical  features  can  be
nonspecific,  and  the  syndrome  often  mimics  infections
(particularly  bacteremia),  neoplastic  diseases  (lymphoma,
leukemia,  hypereosinophilic  syndrome,  paraneoplastic),
autoimmune  or  connective  tissue  conditions  (adult-onset
Still’s  disease,  lupus  erythematosus,  vasculitis).6,10,11,15
Although  no  definitive  laboratory  test  exists  for DRESS,
a  complete  blood  cell  count  can  identify  the characteristic
leukocytosis  with  eosinophilia.18 Nevertheless,  leukopenia
and  lymphopenia  have been  also  reported  and  they  occa-
sionally  precede  leukocytosis.14
Hepatitis  with  isolated  elevation  of  liver  transaminases  is
common.6 A cholestatic  injury  pattern  is  seen  in a minority
of  patients.19
Although  the bilirubin  may  be normal  at  presentation,
hyperbilirubinemia  can  develop  even  after  the causative
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drug  is  discontinued.  Elevations  in liver  enzymes  usually  con-
tinue  to  persist  for  several  days  after  discontinuation  of the
offending  drug.14
Liver  failure,  although  rare,  contributes  to  the leading
causes  of  death.6
The  skin  biopsy  may  help  to  confirm  the diagnosis  but
is  nonspecific.10,20 It  shows  a non-specific  lymphocytic  infil-
trate  of  the  papillary  dermis,  which  may  contain  eosinophils
and  which  is  generally  denser  than  in other  drug reactions.20
DRESS  syndrome  must  be  recognized  promptly  and  the
causative  drug  withdrawn.1,21,22 Indeed,  it  has  been  reported
that  the  earlier  the drug  withdrawal,  the  better  the
prognosis.1
However,  clinical  symptoms  can  be  prolonged  even  after
the  withdrawal  of  culprit  drugs.  In fact,  in the  study  per-
formed  by  Kim  et  al., which  included  48  patients  with  DRESS
syndrome,  clinical  manifestations  persisted  for  1 month.16
Empirical  treatment  with  antibiotics  or  anti-inflammatory
drugs should  not  be  administered  during  the  acute  disease,
since  they  may  confuse  or  worsen  the clinical  picture  of
patients  due  to  an unexplained  cross-reactivity  between
drugs,14 as succeeded  in our  patient.
In  2010,  the  French  Society  of  Dermatology  published
a  consensus  on  the  management  of  DRESS  syndrome.
According  to  this  consensus,  the  absence  of  signs  of
severity,  they  recommend  topical  corticosteroids,  emol-
lients  and  H1-antihistamines.  In  the  presence  of signs  of
severity  (transaminases  greater  than  five  times  normal,
renal  impairment,  pneumonia,  haemophagocytosis  or  car-
diac  involvement),  they  propose  corticosteroids  equivalent
to  1 mg/kg  per  day  of  prednisolone.  If there  are life-
threatening  signs:  haemophagocytosis  with  bone  marrow
failure,  encephalitis,  severe  hepatitis,  renal  failure,  respi-
ratory  failure),  they  suggest  steroids  generally  associated
with intravenous  immunoglobulin  (IVIG)  at a dose of 2  g/kg
over  5  days.  Finally,  in the presence  of  signs  of  severity  with
confirmation  of  major  viral  reactivation,  they  recommend
combining  steroids  and antiviral  (ganciclovir)  and/or  IVIG.21
In  this  case, there  were  signs  of  severity  as  transaminases
were  greater  than  five  times  normal.  For this  reason,  cor-
ticotherapy  was  initiated  with  a good  response,  albeit  the
difficulty  in  doing  the  diagnosis.
The  mortality  rate  is  reported  to  be  between  52 and
20%6,22,23 and  has  been  correlated  with  the  degree  of  hepatic
or  renal  involvement.14
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